Rimegepant News
Rimegepant currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Rimegepant with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
- Evidence level: L5
- Predicted indications (20):
- migraine disorder (100.0%)
- migraine with brainstem aura (99.9%)
- migraine with or without aura, susceptibility to (99.9%)
- atrophoderma vermiculata (99.8%)
- ulerythema ophryogenesis (99.7%)
- heparin cofactor 2 deficiency (99.6%)
- antithrombin deficiency type 2 (99.6%)
- factor 5 excess with spontaneous thrombosis (99.6%)
- thrombophilia (99.0%)
- Prinzmetal angina (98.8%)
- sciatic neuropathy (97.3%)
- homozygous familial hypercholesterolemia (96.7%)
- obsolete susceptibility to ischemic stroke (96.1%)
- stroke disorder (95.6%)
- ABri amyloidosis (94.8%)
- amenorrhea (disease) (93.8%)
- hypoalphalipoproteinemia (93.1%)
- sagittal sinus thrombosis (92.9%)
- lesion of sciatic nerve (91.6%)
- brain stem infarction (89.6%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.